![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2022
Kremsner, Peter G.; Ahuad Guerrero, Rodolfo Andres; Arana-Arri, Eunate; Aroca Martinez, Gustavo Jose; Bonten, Marc; Chandler, Reynaldo; Corral, Gonzalo; Louis De Block, Eddie Jan; Ecker, Lucie; Justin Gabor, Julian; Garcia Lopez, Carlos Alberto; Gonzales, Lucy; Granados Gonzalez, Maria Angelica; Gorini, Nestor; Grobusch, Martin P.; Hrabar, Adrian D.; Junker, Helga; Kimura, Alan; Lanata, Claudio F.; Lehmann, Clara; Leroux-Roels, Isabel; Mann, Philipp; Fernando Martinez-Resendez, Michel; Ochoa, Theresa J.; Alberto Poy, Carlos; Reyes Fentanes, Maria Jose; Rivera Mejia, Luis Maria; Ruiz Herrera, Vida Veronica; Saez-Llorens, Xavier; Schoenborn-Kellenberger, Oliver; Schunk, Mirjam; Sierra Garcia, Alexandra; Vergara, Itziar; Verstraeten, Thomas; Vico, Marisa und Oostvogels, Lidia
(2022):
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
In: Lancet Infectious Diseases, Bd. 22, Nr. 3: S. 329-340
2021
Aldrich, Cassandra; Leroux-Roels, Isabel; Huang, Katell Bidet; Bica, Mihai Alexandru; Loeliger, Edde; Schoenborn-Kellenberger, Oliver; Walz, Lisa; Leroux-Roels, Geert; Sonnenburg, Frank von und Oostvogels, Lidia
(2021):
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
In: Vaccine, Bd. 39, Nr. 8: S. 1310-1318
Kremsner, Peter G.; Mann, Philipp; Kroidl, Arne; Leroux-Roels, Isabel; Schindler, Christoph; Gabor, Julian J.; Schunk, Mirjam; Leroux-Roels, Geert; Bosch, Jacobus J.; Fendel, Rolf; Kreidenweiss, Andrea; Velavan, Thirumalaisamy P.; Fotin-Mleczek, Mariola; Mueller, Stefan O.; Quintini, Gianluca; Schoenborn-Kellenberger, Oliver; Vahrenhorst, Dominik; Verstraeten, Thomas; de Mesquita, Margarida Alves; Walz, Lisa; Wolz, Olaf-Oliver und Oostvogels, Lidia
(2021):
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 A phase 1 randomized clinical trial.
In: Wiener Klinische Wochenschrift, Bd. 133, Nr. 17-18: S. 931-941